Clinical trials: Gastric Cancer
Esophageal Cancer, Gastric Cancer
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
There is no clear standard of care for metastatic stomach or esophageal cancer in the United States. The purpose of this research study is to determine the differences between two regimens of chemotherapy; Arm A: PCA (Cisplatin…
- Conditions
- Esophageal Cancer, Gastric Cancer, Stomach Cancer
- Trial name
- NCT00911820
- Testing
- Bevacizumab, Cisplatin, Irinotecan
- Where
- 4 sites in United States
- Volunteers
- 88 people
- Sponsor
- Dana-Farber Cancer Institute
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastric Cancer, Gastroesophageal Junction Cancer
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Trial name
- MAHOGANY (NCT04082364)
- Testing
- margetuximab, Retifanlimab, Tebotelimab
- Where
- 73 sites in United States, China and 7 more
- Volunteers
- 82 people
- Sponsor
- MacroGenics
Cholangiocarcinoma, Urothelial Cancer
A Study of TAS-120 in Patients With Advanced Solid Tumors
This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120).
- Conditions
- Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors
- Trial name
- NCT02052778
- Testing
- Futibatinib
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 407 people
- Sponsor
- Taiho Oncology, Inc.
Refractory Metastatic Gastric Cancer
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.
- Trial name
- NCT02500043
- Testing
- TAS-102
- Where
- 139 sites in United States, Belarus and 16 more
- Volunteers
- 507 people
- Sponsor
- Taiho Oncology, Inc.
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Gastric Adenocarcinoma
Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer
Gastric cancer is a global health issue as the world's fifth most common malignancy and third leading cause of cancer mortality, respectively. Preoperative radiation therapy may improve overall survival (OS) but is seldom used.
- Trial name
- NCT04162665
- Testing
- Adaptive short course radiation therapy, Standard of care chemotherapy regimen
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Gastric Cancer, Hepatocellular Carcinoma
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on…
- Trial name
- NCT04798781
- Testing
- Telatinib, Keytruda
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Andrew Hendifar, MD
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.
- Trial name
- NCT03449030
- Testing
- TAK-164, 89Zr-TAK-164
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy, Barrett's Esophagus
Pilot Study to Image the Esophagus Using a SECM Tethered Endoscopic Capsule
The goal of this research is to test the imaging quality of the modified, larger diameter, tethered Spectrally Encoded Confocal Microscopy (SECM) capsule in healthy subjects, subjects with Barrett's Esophagus (BE), and subjects…
- Conditions
- Healthy, Barrett's Esophagus, Gastric Acid Reflux
- Trial name
- SECM (NCT02445014)
- Testing
- MGH SECM Imaging Capsule
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Helicobacter Infection
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter pylori is a bacteria that infects the lining of the stomach and is associated with ulcers. Helicobacter pylori may also increase the long-term risk of developing certain forms of gastric cancer.
- Trial name
- 960025 (NCT00656968)
- Testing
- 10-day sequential treatment, 10-day concomitant therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 232 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Gastric Cancer
Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.
- Trial name
- SOLAR (NCT02322593)
- Testing
- TAS-118 plus Oxaliplatin, S-1 plus Cisplatin
- Where
- 6 sites in Japan, South Korea
- Volunteers
- 711 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics (PD), and efficacy of the targeted radionuclide therapeutic CAM-H2 in patients…
- Trial name
- NCT04467515
- Testing
- CAM-H2
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Precirix
Neoplasm, Advanced or Metastatic
A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants
The purpose of this study is to evaluate the relative bioavailability of a new tablet formulation of TAK-117 (new clinical trial material [NTM]) compared to the TAK-117 Process B capsules (current clinical trial material [CTM])…
- Trial name
- NCT02625259
- Testing
- TAK-117, Lansoprazole
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas, that have spread to other places in the body and…
- Conditions
- Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1, Functional Pancreatic Neuroendocrine Tumor, Gastric Neuroendocrine Tumor
- Trial name
- NCT02420691
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or…
- Trial name
- AVAGAST (NCT00548548)
- Testing
- Bevacizumab, Capecitabine, Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 774 people
- Sponsor
- Genentech, Inc.
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Stomach Neoplasms, Metaplasia
Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia
The presence and the extent of gastric intestinal metaplasia(IM) is a good indicator of high risk group of gastric cancer. Many methods was developed to survey it, including multiple gastric biopsy or methylene blue…
- Trial name
- IM (NCT01499576)
- Testing
- Acetic acid chromoendoscopy
- Where
- South Korea
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Konyang University Hospital
Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase I/II trial studies the side effects and the best dose of v-akt murine thymoma viral oncogene homolog (Akt)/mitogen-activated protein kinase 1(ERK) inhibitor ONC201 and to see how well it works in treating patients with…
- Conditions
- Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
- Trial name
- NCT02420795
- Testing
- Akt/ERK Inhibitor ONC201, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center